Dr. Van Zee on Estimating Risk For Surgical Options in DCIS

Kimberly Van Zee, MD
Published: Friday, Sep 30, 2016



Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ (DCIS).

Individualizing treatment for patients with breast cancer has become more important in recent years, says Van Zee. DCIS is somewhat paradoxical in its nature, as there is essentially no risk of metastatic disease or death. However, it also has a higher local recurrence rate in the breast than does invasive cancer.

When it comes to surgical treatment, the options are quite broad, explains Van Zee. They can range from wide excision alone, wide excision with radiation, or with endocrine therapy, to mastectomy or bilateral mastectomy. Overall, it is important to assess a patient's individual values to determine what treatment option is best for her.


Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ (DCIS).

Individualizing treatment for patients with breast cancer has become more important in recent years, says Van Zee. DCIS is somewhat paradoxical in its nature, as there is essentially no risk of metastatic disease or death. However, it also has a higher local recurrence rate in the breast than does invasive cancer.

When it comes to surgical treatment, the options are quite broad, explains Van Zee. They can range from wide excision alone, wide excision with radiation, or with endocrine therapy, to mastectomy or bilateral mastectomy. Overall, it is important to assess a patient's individual values to determine what treatment option is best for her.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x